Biotech Co.* (Symbol) | Pharma Co. (Symbol/Country) | Product |
Amount |
Terms/Details (Date)** |
Affymetrix Inc. (AFFX) |
Novartis Institute | GeneChip Array technology for Functional Genomics (a unit of Novartis AG; Switzerland) |
ND |
The agreement provides for volume-based pricing for GeneChip array purchases and a broad technical collaboration between Novartis Institute and Affymetrix scientists to develop new applications for GeneChip arrays; the Scripps Research Institute and the Novartis Agricultural Discovery Institute also have the option to gain broad access to GeneChip technology (9/99) |
BioFocus plc* (UK) | Glaxo Wellcome SpA (Italy) | Undisclosed compounds | ND | BioFocus will produce high quality, exclusive compounds for Glaxo's drug discovery programs using its SoftFocus range of screening libraries (10/99) |
Corvas International Inc. (CVAS) | Covance Biotechnology Services Inc. (NYSE:CVD) |
rNAPc2 | ND | Corvas entered an agreement with Covance for the manufacture of rNAPc2 for Phase III testing in patients undergoing unilateral, total knee replacement; financial details ND (8/99) |
CytRx Corp. (CYTR) | Nycomed Inc.* |
Flocor, purified poloxamer 188 |
ND | Nycomed will perform purification, testing and release of purified poloxamer 188 in accordance with CytRx specifications and procedures, as well as perform equipment and process validations and assist with regulatory interactions; financial details ND (9/99) |
Duramed Pharmaceuticals Inc. (DRMD) | Solvay Pharmaceuticals Inc.* |
Cenestin tablets, Estratest/Estratest H.S. tablets and Prometrium capsules |
ND |
The companies entered an alliance to jointly market three of their hormone therapies in the U.S.; Duramed will give Solvay an option to purchase a minimum of 1.6M shares and a maximum of 3M shares of common stock at $9 per share (10/99) |
Isis Pharmaceuticals (ISIP) |
Abbott Laboratories (NYSE:ABT) | Isis 2302, an oligonucleotide antisense inhibitor of ICAM-1 |
ND | Abbott will design and build a new manufacturing facility at its North Chicago, Ill., location; Abbott's process development team will lead a joint technical program aimed at optimizing efficiency, scale and costs in collaboration with Isis' proprietary oligonucleotide manufacturing technology; financial details ND (9/99) |
LeukoSite Inc. (LKST) and Ilex Oncology Inc. (ILXO) | Berlex Laboratories Inc. | Campath, a humanized monoclonal antibody |
ND | Berlex obtained exclusive U.S. distribution and marketing rights for Campath from LeukoSite and Ilex; financial details ND (8/99) |
LeukoSite Inc. (LKST) and Ilex Oncology Inc. (ILXO) | Schering AG (Germany; DAX: SCHG) and Berlex Laboratories Inc. (a subsidiary of Schering AG) | Campath, a humanized monoclonal antibody |
$30 | Schering obtained exclusive marketing and distribution rights to Campath in the U.S., Europe and the rest of the world, excluding Japan and East Asia; in the U.S., Schering's subsidiary, Berlex, LeukoSite and Ilex will share profits from the sale of Campath; on sales made in the rest of the territory, Schering will pay royalties equivalent to the rate of profit sharing expected in the U.S.; Schering will make payments of up to $30M for rights to Campath and for the achievement of certain regulatory milestones (8/99) |
Neose Technologies Inc. (NTEC) |
McNeil Specialty Products Co. (a unit of Johnson & Johnson; NYSE:JNJ) |
Undisclosed complex carbohydrates |
ND | The companies have formed a joint venture for the production of bioactive carbohydrates identical to plant-derived carbohydrates; the new venture replaces and expands the previous research and development agreement between the two companies; McNeil and Neose expect to share revenue and profits equally; further details ND (10/99) |
Onyx Pharmaceuticals Inc. (ONXX) | Warner-Lambert Co. (NYSE:WLA) | Onyx-015, an anticancer therapeutic | $55 |
Onyx and Warner will jointly develop and commercialize Onyx-015, in addition to two new armed anticancer viruses; the companies will co-promote the three products in the U.S. and Canada, and will share equally in resulting profits; Warner will commercialize the products in the rest of the world and will pay Onyx a royalty on net sales; Warner will make an up-front payment and equity investment of $15M over the next two years, and will also provide $40M for Phase III trials and ongoing clinical development; in addition to the committed funding, Onyx could receive up to $100M upon achieving certain milestones (10/99) |
Orphan Medical Inc. (ORPH) |
Pierre Fabre Medicament* (France) |
Busulfex injection | ND |
Pierre Fabre will receive exclusive marketing and distribution rights to Busulfex injection in 21 European countries, Argentina and South Africa; financial details ND (10/99) |
Palatin Technologies (PLTN) |
Mallinckrodt Inc. (NYSE:MKG) |
LeuTech, a radiolabeled monoclonal antibody for diagnosing infection |
$13.5 | Mallinckrodt licensed LeuTech, and will have exclusive marketing rights upon FDA approval; Mallinckrodt paid Palatin a license fee of $0.5M and an additional $13M to purchase 0.7M unregistered, unrestricted shares of Palatin common stock; Palatin will receive an additional $10M upon FDA approval of the first LeuTech indication and on attainment of certain sales goals following product launch; Mallinckrodt will reimburse Palatin for 50% of development costs; Palatin will manufacture Leutech and receive a transfer price on each product unit and a royalty on net sales (8/99) |
Pharming Group N.V. (the Netherlands; EASDAQ:PHAR) |
DSM Biologics* (the Netherlands) |
Recombinant human lactoferrin |
ND |
Pharming and DSM signed an agreement for the purification of recombinant human lactoferrin from the milk of transgenic cows; further details ND (9/99) |
Seragen Inc. |
F. Hoffmann-La (a subsidiary of Ligand Pharmaceuticals Inc.; LGND) |
Products Roche Ltd. (Switzerland) and its U.S. subsidiary, Hoffmann-La Roche containing the active ingredient daclizumab |
$2.5 | Seragen entered a non-exclusive sublicense agreement with U.S.- and Switzerland-based Roche with respect to Seragen's rights under the Strom patents family; Roche receives the right to make, use and sell in the U.S., Canada, Australia and New Zealand any product containing the active ingredient daclizumab, including Zenapax, a product Roche currently markets; Seragen will receive a $2.5M royalty for previous sales of Zenapax, plus royalties on net sales of licensed products in the U.S., Canada, Australia and New Zealand; Seragen will also receive milestone payments in the event Roche receives U.S. regulatory approval of licensed products containing daclizumab for the treatment of autoimmune indications (9/99) |
Synsorb Biotech Inc. (Canada; SYBB; TSE:SYB) |
Paladin Labs Inc. (Canada; VSE:PLB) | Synsorb Cd, a therapeutic for the recurrent form of Clostridium difficile-associated diarrhea | ND |
Paladin received exclusive marketing and distribution rights for Synsorb Cd; the companies will share equally in future revenues from Canadian sales; Synsorb will continue development of the product, and will manufacture and supply it to Paladin; Paladin will be responsible for all aspects of the marketing and sale of the product in Canada; financial details ND (9/99) |
NOTES: | ||||
# This chart does not include any marketing and/or distribution agreements that involve agricultural product development. The information in the chart covers the time period between 7/1/99 and 10/31/99. | ||||
ND 3D Not disclosed, reported and/or available | ||||
* Private companies are indicated with an asterisk. | ||||
** The dates listed are the dates of press releases. They are not necessarily the dates on which transactions took place. |
||||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | ||||
AMEX 3D American Stock Exchange; NYSE 3DNew York Stock Exchange; TSE 3D Toronto Stock Exchange; VSE 3D Vancouver Stock Exchange |